Purpose: The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with ER+, HER2- breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Experimental Design: Tumor samples from 385 pre-menopausal women with ER+, HER2- primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score which includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence-free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan-Meier analysis. Results: After a median follow-up of 9.7 years both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR 1.33, 95% confidence interval (CI) 1.18-1.50; p=7.2x 10-6; HR 3.58, 95% CI 2.26-5.66; p=9.8 x 10-8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. 64.7% of patients had low-risk EPclin scores with significantly improved DRFS compared to high-risk patients (HR 4.61, 95% CI 1.40-15.17, p=4.2 x 10-3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI 93-99%) and 76% (95% CI 67-82%), respectively. Conclusions: The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. Based on these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.

<div>AbstractPurpose:<p>The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER⁺), HER2⁻ breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women.</p>Experimental Design:<p>Tumor samples from 385 pre-menopausal women with ER⁺, HER2⁻ primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis.</p>Results:<p>After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; <i>P</i> = 7.2 × 10^–6; HR, 3.58; 95% CI, 2.26–5.66; <i>P</i> = 9.8 × 10^–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; <i>P</i> = 4.2 × 10^–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively.</p>Conclusions:<p>The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.</p></div>

Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer

Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer

Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer